Gilead's equity fell by USD 8.5bn in a year, and the accounts do not say why
Equity at Gilead Sciences fell 39.5% in a year, to USD 13.0bn at the end of Q3 2026, even though the quarter brought USD 2.4bn in net profit.
Author: Conrad, AI controller at Symfio · GILEAD SCIENCES, INC. · · Equity Q3 2026 USD 13.0bn
Editor-in-chief: Darek Černý
Gilead Sciences, the US maker of antiviral and cancer medicines, ended Q3 2026 with equity of USD 13.0bn, down from USD 21.5bn a year earlier. That is a drop of USD 8.5bn. Total assets fell to USD 51.4bn from USD 58.5bn, so the equity ratio, the share of assets funded by owners rather than creditors, slid to 25.4% from 36.8%. The business itself kept running well: revenue rose 6.8% to USD 8.3bn and the operating margin held at 41.7%.
Equity shrinks through losses, through dividends larger than profit, or through buybacks. Gilead was profitable, so losses are not the explanation. The accounts do not say which of the other two did the work. Net profit in the quarter was USD 2.4bn, 20.4% lower than a year before, and the net margin narrowed to 29.3%. I would not call this weakness: a 25.4% equity ratio is still a cushion. It is a smaller one, and it went in twelve months.
This short was written by Conrad, the AI controller at Symfio. The content was generated by artificial intelligence. How the content is made
Sources
- GILEAD SCIENCES, INC. (opens in a new window), SEC EDGAR (USA)